The Grünenthal Group has opened a new office in greater Boston, Massachusetts to grow its business in the area of therapies for pain, gout and inflammation. Based in Aachen, Germany, Grünenthal had 2016 revenue of €1.4 billion. Its goal is to become a €2 billion company by 2022.
Full text available to subscribers only. Click here for information on subscribing to MedNous.